The influence of polymorphic variants rs2305619 и rs3816527 of the PTX3 gene on clinical profile and outcomes in patients with hypertrophic cardiomyopathy: results of a 11-years follow-up

The objective of this study was to determine the association of polymorphic variants rs2305619 and rs3816527 of the PTX3 gene with clinical profile and outcomes in hypertrophic cardiomyopathy (HCM) patients.

Methods and materials. The study population consisted of 153 patients ≥18 years old with a confirmed diagnosis of HCM. The control group included 200 healthy donors. Duration of follow-up was 11 years (2008–2019 yrs.). The study design included a new model for determining variants of the clinical profile and outcomes of HCM. Polymorphic variants rs2305619 and rs3816527 of the PTX3 gene were genotyped by polymerase chain reaction.

Results. The mortality rate in patients ≥18 years old with 1, 2 and 3 adverse pathways of HCM progression was significantly higher, compared with those without adverse pathways (р<0.001). A combination of chronic heart failure (CHF) with midrange and reduced LVEF (<49 %) with 1, 2 and 3 adverse pathways in HCM patients occurred more frequently, compared with those who had CHF with preserved LVEF (≥50 %) (odds ratio (OR) = 0.168, 95 % confidence interval (CI) =0.068–0.412, р<0.001). The genetic testing showed no significant differences in genotype and allele frequencies of polymorphic variants rs2305619 and rs3816527 of the PTX3 gene in patients with HCM and control groups. It was found a tendency for increase in GG genotype frequency (p<0.068) and significant increase in G allele frequency of rs2305619 of the PTX3 gene in HCM patients ≥18 years old and CHF with mid-range and reduced LVEF (<49 %) (A:G, OR=0.521, 95 % CI=0.301–0.902, p<0.019). HCM patients (age – 63 [58; 75] years) and type 2 diabetes mellitus demonstrated high prevalence in AG and GG genotypes (p<0.008) and G allele frequencies of rs2305619 of the PTX3 gene (A:G, OR =1.952, 95 % CI=1.076–3.542, p<0.026).

Conclusions. HCM progression along 1 and more adverse pathways in patients ≥18 years old has been characterized with adverse outcome. G allele of rs2305619 of the PTX3 gene is associated with CHF with mid-range and reduced LVEF (<49 %) in HCM patients ≥18 years old. The associations of G allele and AG and GG genotypes of rs2305619 of the PTX3 gene with diabetes type 2 are observed in elderly HCM patients.

1. Iyngkaran P., Liew D., Neil C., Driscoll A., Marwick T. H., Hare D. L. Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clinical Medicine Insights // Cardiology. 2018;(12):1179546818809358. Doi: 10.1177/1179546818809358.

2. Yancy C. W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America // Circulation. 2017;136(6):E137–E161. Doi: 10.1161/CIR.0000000000000509.

3. Garlanda C., Bottazzi B., Magrini E., Inforzato A., Mantovani A. PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer // Physiological reviews. 2018;98(2):623–639. Doi: 10.1152/physrev.00016.2017.

4. Du Clos T. W. Pentraxins: structure, function, and role in inflammation // ISRN Inflammation. 2013;(2013):379040. Doi: 10.1155/2013/379040.

5. Latini R. Gullestad L. Masson S. et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials // European Journal of Heart Failure. 2012;14(9):992–999. Doi: 10.1093/eurjhf/hfs092.

6. Liu H., Guo X., Yao K., Wang C., Chen G., Gao W., Yuan J., Yu W., Ge J. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure // BioMed research international. 2015;(2015):817615. Doi: 10.1155/2015/817615.

7. Authors/Task Force members, Elliott P. M., Anastasakis A., Borger M. A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: theTask Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) // European Heart Journal. 2014;35(39):2733–2779. Doi: 10.1093/eurheartj/ehu284.

8. Rowin E. J., Maron M. S., Chan R. H., Hausvater A., Wang W., Rastegar H., Maron B. J. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy // The American Journal of Cardiology. 2017;120(12):2256–2264. Doi: 10.1016/j.amjcard.2017.08.048.

9. Naito A., Tanabe N., Jujo T., Shigeta A., Siguira T., Sakao S., Ishida K., Tatsumi K. Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism // PLoS One. 2014;9(11):E113086. Doi: 10.1371/journal.pone.0113086.

10. Maron B. J., Rowin E. J., Udelson J. E., Maron M. S. Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy // JACC Heart Failure. 2018;6(5):353–363. Doi: 10.1016/j.jchf.2017.09.011.

11. Fujino N., Konno T., Hayashi K., Hodatsu A., Fujita T., Tsuda T., Nagata Y., Kawashiri M. A., Ino H., Yamagishi M. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy // Clinical Cardiology. 2013;36(3):160–165. Doi: 10.1002/clc.22082.

12. Hartiala J., Schwartzman W. S., Gabbay J., Ghazalpour A., Bennett B. J., Allayee H. The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities // Current atherosclerosis reports. 2017;19(2):6. Doi: 10.1007/s11883-017-0641-6.

13. Poliakova A. A., Semernin E. N., Streltcova A. A., Kostareva A. A., Gudkova A. Y. Hypertrophic cardiomyopathy in elderly people // Arterial’naya Gipertenziya = Arterial Hypertension. 2013;19(6):502–505. (In Russ.). Doi: 10.18705/1607-419X-2013-19-6-502-505.

14. Kovalevskaya E. A., Krylova N. S., Poteshkina N. G. Hypertrophic cardiomyopathy and ischemic heart disease: the problem of pathology combination // Kardiologiia. 2018;58(1S):31–35. (In Russ.). Doi: 10.18087/cardio.2386.

15. Maron M. S., Finley J. J., Bos J. M., Hauser T. H., Manning W. J., Haas T. S., Lesser J. R., Udelson J. E., Ackerman M. J., Maron B. J. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy // Circulation. 2008;118(15):1541–1549. Doi: 10.1161/CIRCULATIONAHA.108.781401.

16. Towe E. C., Bos J. M., Ommen S. R., Gersh B. J., Ackerman M. J. Genotype-Phenotype Correlations in Apical Variant Hypertrophic Cardiomyopathy // Congenital Heart Disease. 2015;10(3):E139–E145. Doi: 10.1111/chd.12242.

17. Streltsova A. A., Gudkova A. Y., Bezhanishvili T. G., Kozyreva A. A., Muravyev A. S., Andreeva S. E., Krutikov A. N., Semernin Е. N., Pyko S. A., Khmelnitskaja K. A., Sitnikova M. Y., Kostareva A. A. Gender-specific differences in clinical profile of hypertrophic cardiomyopathy and their association with the polymorphic variant rs1739843 of the hspb7 gene // Arterial’naya Gipertenziya = Arterial Hypertension. 2019;25(5):478–488. (In Russ.). Doi: 10.18705/1607-419X-2019-25-5-478-488.

18. Zhu H., Yu W., Xie Y., Zhang H., Bi Y., Zhu D. Association of Pentraxin 3 Gene Polymorphisms with Susceptibility to Diabetic Nephropathy // Medical science monitor: international medical journal of experimental and clinical research. 2017;(23):428–436. Doi: 10.12659/msm.902783.